DISTINCTIVE

seconD- line folfiri aflIbercept in proSpecTIvely stratified, anti-egfr resistaNt, metastatic coloreCTal  cancer patIents with ras validated wild typstatus (distinctive)

AFLIBERCEPT POST ANTI-EGFR IN CCR

· Dynamic changes of pro-angiogenic factors during FOLFIRI-aflibercept treatment – interim analysis of DISTINCTIVE trial

Scarica il file  

· Monocyte to red blood cells ratio (MRR): an innovative haematologic prognostic parameter in FOLFIRI-aflibercept treated patients – a subgroup analysis from the DISTINCTIVE trial

Scarica il file